Spectrum of antihypertensive therapy in South Asians at a tertiary care hospital in Pakistan. by Almas, Aysha et al.
eCommons@AKU
Department of Medicine Department of Medicine
September 2011
Spectrum of antihypertensive therapy in South
Asians at a tertiary care hospital in Pakistan.
Aysha Almas
Aga Khan University
Salik Ur Rehman Iqbal
Anabia Ehtamam
Aamir Hameed Khan
Follow this and additional works at: http://ecommons.aku.edu/pakistan_fhs_mc_med_med
Part of the Circulatory and Respiratory Physiology Commons
Recommended Citation
Almas, A., Ur Rehman Iqbal, S., Ehtamam, A., Khan, A. (2011). Spectrum of antihypertensive therapy in South Asians at a tertiary
care hospital in Pakistan.. BMC Research Notes, 4, 318.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_med_med/103
RESEARCH ARTICLE Open Access
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Abstract
Background: Despite available guidelines on hypertension (HTN), use of antihypertensives is variable. This study
was designed to ascertain frequency of patients on monotherapy and > 1 antihypertensive therapy and also to
ascertain proportion of patients on diuretic therapy.
Methods: It was a crossectional study conducted on 1191 adults(age > 18 yrs)hypertensive patients selected by
computerized International Classification of Diseases -9-coordination and maintenance (ICD-9-CM) presenting to a
tertiary care hospital in Pakistan. Data on demographics, comorbids, type of antihypertensive drug, number of
antihypertensive drug and mean duration of antihypertensive drug was recorded over 1.5 year period (2008-09).
Blood pressure was recorded on admission. Primary outcome was use of combination therapy and secondary
outcome was use of diuretic therapy.
Results: A total of 1191 participants were included. Mean age(SD) was 62.55(12.47) years, 45.3%(540) were males.
Diabetes was the most common comorbid; 46.3%(551). Approximately 85% of patients had controlled
hypertension. On categorization of anti hypertensive use into 3 categories;41.2%(491) were on monotherapy,32.2%
(384) were on 2 drug therapy,26.5%(316) were on ≥3 drug therapy. Among those who were on monotherapy for
HTN;34%(167) were on calcium channel blockers,30.10%(148) were on beta blockers, 22.80%(112) were on
Angiotensin converting enzyme (ACE) inhibitors,12%(59) were on diuretics and 2.20%(11) were on Angiotensin
receptor blockers(ARB). Use of combination antihypertensive therapy was significantly high in patients with
ischemic heart disease(IHD)(p < 0.001). Use of diuretics was in 31% (369) patients. Use of diuretics was significantly
less in patients with comorbids of diabetes (p 0.02), Chronic kidney disease(CKD)(p 0.003), IHD (p 0.001) respectively
Conclusion: Most patients presenting to our tertiary care center were on combination therapy. Calcium channel
blocker is the most common anti hypertensive drug used as monotherapy and betablockers are used as the most
common antihypertensive in combination. Only a third of patients were on diuretic as an antihypertensive therapy.
Background
Hypertension is a leading contributor to the global bur-
den of cardiovascular morbidity and mortality [1].
Despite availability of antihypertensive drugs and recom-
mendation to control hypertension by several bodies,
control of hypertension below levels of < 140 systolic
and < 90 diastolic is not uniform [2]. Hypertension con-
trol has improved from 27.3% in 1988-1994 to 50.1% in
2007-2008 in the United States [3]. However hyperten-
sion control rates are barely 6% in countries like
Pakistan, China and India [4]. Every, one in three adult
aged 40 years and above in Pakistan is hypertensive [5].
Hence the magnitude of the problem for a developing
economy like Pakistan is immense.
Several reasons have been highlighted as cause of such
high rates of uncontrolled hypertension. Apart from
unhealthy lifestyles, lack of awareness about hyperten-
sion, distorted public health systems, physicians treating
hypertension also lag behind in treating hypertension
according to standard guidelines [5,6]. Non compliance
to antihypertensive therapy is also a reason for uncon-
trolled hypertension. Forty three percent patients pre-
senting to outpatient setting at a tertiary care center
were not fully compliant in taking antihypertensive
medications [7].
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The Seventh Report of the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (JNC7) recommends diuretic to be
used as preferred initial antihypertensive agent alone or
in combination [8]. On the other hand excellent clinical
trial data suggest that other groups of Antihypertensives
like the Angiotensin converting enzyme inhibitor
(ACEIs) reduce the complications of hypertension
[9,10]. All of the current guidelines suggest that ≥ 1
antihypertensive agent is required in most patients with
hypertension to reach BP goals that will effectively
reduce the cardiovascular risk [9,11]. Hence there is
wide variation in the prescription of antihypertensive
medications by physicians all over the world [12]. Four
classes of these drugs, including Calcium channel block-
ers(CCBs), Beta blockers(b-blockers), Angiotensin con-
verting enzyme inhibitors(ACE)/Angiotensin receptor
blockers(ARB) and diuretics are the most prescribed
antihypertensive drugs class in many parts of the world
[13-15].
Data on the use of antihypertensive in individual spe-
cialty practices has been reported from the Indo-Asian
region. There have been studies advocating the use of
ACEIs in stroke patients and use of ARB in normoten-
sive diabetic patients. Hence this data is specific to a
certain patient population [16,17]. Currently no robust
data on monotherapy and combination therapy are
known from this region. Also overall use of diuretics,
the first line recommended antihypertensive therapy,
along with other antihypertensives from this region is
not available. Hence we designed this study to elucidate
the spectrum of antihypertensive therapy in South Asian
population at a tertiary care center and ascertain fre-
quency of patients on monotherapy and > 1 antihyper-
tensive therapy. Secondary objective was to determine
proportion of patients on diuretic as an antihypertensive
therapy.
Methods
Study design and study population
This was a cross sectional study conducted at the Aga
Khan University, Karachi, Pakistan. The Aga Khan Uni-
versity Hospital (AKUH) has 563 beds in operation and
provides services to over 50,000 hospitalized patients
and to over 600,000 outpatients annually with the help
of professional staff and facilities that are among the
best in the region. Care is available to all patients in
need. Those who are unable to pay for treatment,
receive assistance through a variety of subsidies. AKUH
is the first hospital in Pakistan and among the first few
teaching hospitals in the world to be awarded the presti-
gious Joint Commission International Accreditation
(JCIA) for practicing the highest internationally recog-
nized quality standards in health care. Similarly, the
Hospital also holds ISO 9001: 2008 certification for
practicing consistent international standards of quality
services http://www.aku.edu. Ethical approval from the
ethics review committee of the Aga Khan University
(letter dated 16-08-2009) was taken for conduct of the
study
All adult inpatients(> 18 yrs), over a 1.5 year period
(2008-2009), who were known hypertensive (diagnosed
on having an average blood pressure of ≥140/90 mm Hg
on at least 2 clinic visit)and were on antihypertensive
therapy for at least 6 weeks were included [8]. Antihy-
pertensives were prescribed by general physicians, inter-
nist and medicine subspecialists. A sample of 1191
consecutive hypertensive patients admitted to the hospi-
tal was selected. This sample was drawn using compu-
terized medical record system International
Classification of Diseases -9-coordination and mainte-
nance (ICD-9-CM) at health information management
system in the hospital. Patients admitted either with pri-
mary or secondary diagnosis of hypertension was used
for selection through the ICD -9-CM. Those patients
who did not have a documented record of the antihy-
pertensive therapy were excluded from the study. All
patients gave a general consent on admission; however
informed consent was not taken as data was later
extracted through ICD-9-CM.
Study variables and measurements
Primary outcome variable was use of combination anti-
hypertensive therapy. It had three categories; monother-
apy, two drug therapy and ≥three drug therapy.
Secondary outcome was use of diuretics as an antihyper-
tensive therapy. Data on demographics, co morbid con-
ditions, type of antihypertensive drug, number of
antihypertensive drugs and mean duration of antihyper-
tensive drug therapy was recorded by trained data col-
lectors. Records of antihypertensive drugs were
extracted from the medical record of the patient. A two
way approach was used for this purpose. Anti hyperten-
sives documented on the initial assessment sheets filled
at the time of admission was recorded. This was also
reconfirmed from the record of the last clinic visit for
every patient. In case the clinic visit was at some other
hospitals, that prescription was used for the second con-
firmation. It was assumed that the patients were compli-
ant to the medications written, however no additional
measures were used to check compliance. Patients who
used an antihypertensive medication with only 1 active
ingredient were defined as receiving monotherapy.
Those taking more than 1 active ingredient (either in 1
combination pill or in 2 different single pills) were
defined as receiving polytherapy [12]. A history of physi-
cian-diagnosed diabetes, stroke, ischemic heart disease
(IHD), Chronic kidney disease(CKD) as documented in
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the medical records was noted. Diabetes was defined as
fasting plasma glucose ≥126 mg/dl at a prior visit [18].
Stroke was defined clinically as an acute neurologic dys-
function of vascular origin with sudden(within seconds)
or at least rapid (within hours)occurrence of symptoms
and signs corresponding to the involvement of focal
areas in the brain [19]. Ischemic heart disease was diag-
nosed using WHO definition [20]. CKD was defined as
rise in serum creatinine of > 1.2 mg/dl for 3 months
[21].
First two readings of blood pressure on admission
were recorded. At the time of admission BP in the right
arm were recorded using a mercury sphygmomanometer
with the individual in the sitting position. Controlled
blood pressure was defined as systolic blood pressure
(SBP) < 140 mm Hg or diastolic blood pressure(DBP) <
90 mm Hg and uncontrolled blood pressure was defined
as SBP > 140 mm Hg and DBP > 90 mm Hg [8]. Any
change in antihypertensive medications during inpatient
stay was not recorded.
Statistical analysis
Statistical package for social sciences (SPSS) 17.1 was
used for the analysis. Mean and standard deviation was
used for quantitative variables and frequency and per-
centage for qualitative variables. Comparison of qualita-
tive variables was done by chi square test and of
quantitative variables by independent sample t test and
analysis of variance. p value of < 0.05 was taken as
significant.
Results
A total of 1191 participants were included. The mean
age (SD) was 62.5(12.4) years, 45.3%(540) were males.
Comorbids conditions and ovearall blood pressure read-
ings are shown in Table 1. Eighty five percent of
patients had controlled hypertension.
Monotherapy and combination antihypertensive therapy
On categorization of anti hypertensive into 3 categories;
41.2%(491) were on monotherapy,32.2%(384) were on 2
drug therapy and 26.5%(316) were on ≥3 drug therapy.
Comparison is shown in Table 1. Among the three
groups, use of mono and dual therapy was significantly
increased in patients IHD(p < 0.001). Most diabetics
(42%) were on monotherapy. Mean (SD) SBP readings
in diabetics were as follows;139.2 (23.7)mm hg for
monotherapy,134.9(25.2) mm Hg for 2 drug combina-
tion, 136.8(25.1)mm Hg for ≥3 drug combination
respectively. Mean (SD) DBP readings in diabetics were
as follows;77.7 (11.9)mm hg for monotherapy,76.2(12.8)
mm Hg for 2 drug combination, 77.2(15.5)mm Hg for >
3 drug combination respectively. Distribution of classes
of antihypertensive drugs in hypertensive patients on
monotherapy and combination therapy is shown in Fig-
ure 1. Calcium channel blockers were used most com-
monly as monotherapy; 34%(167) and beta blockers
were used as the most common antihypertensive in
combination therapy;59.1(41.4)
Diuretics as an antihypertensive therapy
Thirty one percent patients were on diuretic as antihy-
pertensive therapy. Use of diuretics is significantly
decreased in patients with the following comorbids(on
diuretic v not on diuretic); diabetes (33% v 66%;p 0.02),
CKD (43% v 66%;p 0.003), IHD (37% v 63%;p 0.001)
respectively. There was no significant difference in SBP
(p 0.10) and DBP (p 0.50) of patients on diuretics com-
pared to not on diuretics.
Discussion
This data of 1191 Southasian patients at atertiary care
center show that, most hypertensive patients were on
combination therapy. Patients with IHD, CKD were
more likely to be on 2 drug combination antihyperten-
sive therapy. Calcium channel blockers were used as the
most common antihypertensive monotherapy and beta-
blockers as most common antihypertensive in combina-
tion. Diuretics as monotherapy antihypertensive was
used in one third of the patients.
Recent clinical trials suggest that the approach of
using monotherapy for the control of hypertension is
not likely to be successful in most patients and espe-
cially in those with some comorbids conditions. (eg.
DM, heart failure). The achievement of BP goal typically
requires 2 or more medications in various settings
[22-24]. This study shows that two thirds of the patients
were on combination therapy. However when combina-
tion therapy is replaced by other generic substitutes of
the drug it results in poor drug adherence in Pakistani
immigrants to Norway [25].
The approach of combination therapy may be theore-
tically favored by the fact that multiple factors contri-
bute to the hypertension and achieving control of BP
with single agent and adding a second agent may lead
to better control, acting by complimentary mechanism
[11]. Adherence to goal guidelines is better than adher-
ence to treatment guidelines as refelected by the SBP
and DBP reported in this study and addition of a third
antihypertensive does not decrease the BP further on.
Walker reports from the antihypertensive drug prescrip-
tion trends, a study over a11 year period that drug pre-
scription for antihypertensive combination therapy has
increased in all provinces of Canada; Among drug classi-
fications, angiotensin receptor blockers had the largest
increase for single-drug therapy and angiotensin-con-
verting enzyme inhibitors-diuretics for combination-
drug therapy [26]. However forty percent of diabetics
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were on monotherapy. Recommended goal of blood
pressure (BP) is < 130/80 mm Hg in hypertensives with
diabetes mellitus (DM) [27]. This study shows that the
target blood pressure as recommended for diabetes was
not observed in these patients and this may be attribu-
ted to inadequate use of combination therapy. Therefore
inadequate use of combination therapy may be one of
the reasons of uncontrolled hypertension in diabetics
and requires further research. This also highlights the
fact that goal attainment is more important than choice
of agent.
Calcium channel blockers have emerged as the most
common monotherapy used for hypertension, whereas
Beta blockers have been used as the most common
combination therapy for hypertension. Calcium channel
blockers have been the preferred monotherapy in many
studies followed by beta blockers and ACE inhibitors
[28-31]. ACE inhibitors are found as the most com-
monly used therapy in other parts [32]. In a cross-sec-
tional screening study conducted in 1000 primary care
units considered to be representative of primary care in
Turkey most frequently used antihypertensive drug
class was angiotensin-converting enzyme inhibitors
(30.1%), followed by beta-blockers (20.6%), calcium-
channel blockers (17.9%), diuretics (15.4%) and angio-
tensin-receptor blockers (14%) [33]. Hence calcium
channel blockers are used as the most common antihy-
pertensive therapy in the Indo Asian region. While cal-
cium channel blockers and beta blockers have surpassed
all other antihypertensives as the first line agent used as
monotherapy, guidelines all over the world recommend
use of low dose thiazide diuretic as the first line drug
for essential hypertension [8,34]. Hence, this study indi-
cates that the clinical practice patterns are similar to
other parts of the world. This study reports that only
31% patients are on diuretic therapy, which is clearly a
low usage compared to what is recommended. Such
trends of lower usage of diuretics have also been found
in studies conducted in Norway and France [14]
Although diuretics are recommended as first line ther-
apy, are ranked as third in total antihypertensive drug
utilization [35]. The reason for the low usage in this
population could be multiple and needs further
research. Firstly physicans tend not to prescribe
Table 1 Comparison of hypertensive patients on monotherapy versus combination antihypertensive therapy
Characteristics Overall Mono therapy dual therapy > 3 drugtherapy P value*
%(n)
N = 1132**
%(n)
41.2(491)
%(n)
32.2(384)
%(n)
14.8(176)
Age(years)
mean (SD)
62.5(12.47) 62.8(12.3) 62.2(12.4) 62.5(12.6) 0.75
Age groups(years)
18-39
3.3(39) 43.6(17) 28.2(11) 28.2(11)
40-59 33.8(402) 39.1(157) 36.3(146) 24.6(99)
≥60 62.8(748) 42.2(316) 30.3(227) 27.4(205) 0.33
Gender
males
45.3(540) 42.1(216) 32.4(166) 29.3(158) 0.14
Comorbids conditions
Diabetes 46.3(551) 41.2(219) 34.0(181) 27.4(151) 0.62
Chronic kidney disease 8.9(106) 34.6(36) 38.5(40) 28.3(30) 0.25
Ischemic heart disease 34.9(416) 33.6(137) 36.3(148) 31.5(131) < 0.001
Stroke 11.6(138) 41.4(55) 36.1(48) 25.4(35) 0.9
Chronic liver disease 4.7(56) 41.8(23) 34.5(19) 25(14) 0.91
Systolic Blood pressure
mean (SD)
136.2(25) 136.2(23.98) 135.6(25.05) 136.8(27.2) 0.8
Diastolic blood Pressure
mean (SD)
77.66(14) 77.7(12.90) 77.4(14.28) 77.7(16.5) 0.9
*p value < 0.05 is significant; it is for the groups(monotherapy,2 drug therapy and ≥3 drug therapy)
**59 patients had missing records for comorbids
Figure 1 Distribution of classes of antihypertensive drugs in
hypertensive patients on monotherapy and combination
therapy.
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diuretics due to fear of an adverse electrolyte imbalance,
like hyponatremia, which specially in the geriatric popu-
lation could have detrimental effects [36]. Secondly, pro-
motional activity of pharmaceutical could be such that
more marketing is done for the newer antihypertensives
like ARB [37].
The strength of this study is the large sample size, and
is the first study from this region to report figures on
monotherapy, combination therapy and type of antihy-
pertensives in hypertensives. However there are several
limitations in our study. Firstly it has limited external
validity as the sample is not representative for an entire
population. It represents population visiting a standard
hospital, hence is not representative of entire Pakistan.
Secondly certain amount of recall bias may be involved
as information about the antihypertensives was taken
from the medical records. Thirdly the crossectional
design of the study cannot strongly give a cause and
effect association. Fourthly only one blood pressure
reading has been taken into account, hence some of the
patients may have been misclassified as controlled
hypertensives. Also compliance and cost of antihyper-
tensives was not assessed for each patient.
Conclusion
Most patients presenting to our tertiary care center were
on combination therapy. Calcium channel blocker is the
most commonly used anti hypertensive drug used as
monotherapy while betablockers is used as the most
common combination therapy. Diuretics use in hyper-
tensive patients is low and not keeping with the recom-
mended guidelines.
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